Thyrocare Technologies Ltd reported a strong performance for the July –September quarter, with net profit rising 79% year-on-year to ₹48 crore, supported by higher test volumes and improved efficiency.

Revenue climbed 22% to ₹216.5 crore from ₹177.4 crore a year earlier, while EBITDA grew 47.5% to ₹71.3 crore. Operating margins expanded to 32.9% from 27.2%.

In the pathology segment, franchise revenue grew 20% year-on-year, while partnership revenue recorded a robust 35% increase, underscoring continued expansion in both core and allied services.

The diagnostics chain processed 53.3 million tests during Q2 FY26, a 21% year-on-year growth, reaffirming its position as India’s largest diagnostic test volume processor.

The company remains debt-free on a consolidated basis, holding net

See Full Page